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In the early 1990s, former Michigan supreme court Justice
Thomas Brennan became disillusioned with popular law
school rankings and so decided to survey 100 academics,
judges, and lawyers on his own, asking them to rank a list of
ten schools he provided. He used a composite index similar
in structure, but different in content, to those used by main-
stream surveyors, such as U.S. News & World Report.A s
expected, many of the big name schools—Harvard, Yale,
Stanford—made it to the top of the list. Penn State, as
Brennan recalled, “[Was] about in the middle of the pack.
Maybe fifth among the 10 schools listed.” There was one
small problem, however. Penn State had no law school at the
time. Brennan had included it to make a point: surveys are
limited by both the quality of the questions asked and by
how familiar respondents are with the subject being surveyed
[1, 2].
Similar surveys using questionnaires are employed com-
monlyinmedicineand,whenwell-designedandimplemented,
can provide valuable information regarding perceptions, pref-
erences, and practice patterns—a finger on the pulse, if you
will, of current treatment approaches [3, 4]. Almost without
exception, variation is the rule in such surveys. Engstrom and
colleagues, for example, published in 1991 the results of a
surveyof62treatinguveitisspecialistsinthe AmericanUveitis
Society (AUS) regarding what were then current practices in
the management of ocular toxoplasmosis [5]. While a sizable
proportion of respondents viewed poor vision (<20/200),
marked or severe vitreous inflammation, and zone 1 lesion
location [6] as absolute indications for antimicrobial therapy,
the extent to which experts reached agreement regarding when
to initiate treatment was by no means absolute. Moreover, the
lack of consensus was even more striking when considering
which agent(s) to choose. Specifically, experts reported use of
ten different antimicrobial drugs in more than four different
combinations, with approximately one third recommending a
combination containing pyrimethamine, folinic acid, sulfadia-
zine, and prednisone. Holland and Lewis updated this survey
in 2002, publishing the results gathered from 79 respondents
who evaluated and managed patients with ocular toxoplasmo-
sis [7]. Similar “absolute treatment indicators” were identified,
but this time 11 different agents were used in an equal number
of combinations, including some not mentioned in the 1991
survey. Once again, the most common approach involved the
combined use of pyrimethamine,folinic acid, sulfadiazine,and
prednisone—although more than two thirds recommended
other single or combination agent treatment regimens. Similar
trends and variations in treatment approach were observed
when uveitis specialists were surveyed in 2011 by Wakefield
and associates [8]—fully 20 years after the original ocular
toxoplasmosis practice survey was published. Even greater
variation regarding indicators of treatment exists among non-
uveitis specialists [9].
One thing well-designed surveys of medical practitioners
can doparticularlywell isidentifylimitations and deficiencies
in the level and understanding of current clinical knowledge,
E. T. Cunningham Jr.
California Pacific Medical Center,
San Francisco, CA, USA
E. T. Cunningham Jr.
Department of Ophthalmology,
Stanford University School of Medicine,
Stanford, CA, USA
E. T. Cunningham Jr. (*)
West Coast Retina Medical Group,
185 Berry Street, Lobby 2, Suite 130,
San Francisco, CA 94107, USA
e-mail: emmett_cunningham@yahoo.com
J Ophthal Inflamm Infect (2012) 2:61–63
DOI 10.1007/s12348-012-0061-2including familiarity with and adherence to published guide-
lines. This was nicely demonstrated by Nguyen and col-
leagues in 2010, when the authors published the results of a
survey regarding treatment of noninfectious uveitis as
reported by 60 ophthalmologists and three rheumatologists
[10]. Striking among the reported findings was the extent to
which treatment patterns differed from recommended guide-
lines published byanexpertpanel roughly 10years prior [11].
This was particularly so regarding the long-term use of oral
corticosteroids, which tended to be used at doses three to four
times the recommended maximal dose for chronic therapy of
10 mg/day. Similarly striking was the use of corticosteroid
sparing agents, which were introduced to lower systemic
corticosteroid doses to or below 10 mg/day in only 12% of
patients. In fact, 75% of surveyed physicians did not use and
were not aware of the existence of uveitis treatment guide-
lines. Among the ophthalmologists surveyed by Nguyen and
associates, only 19 (32%) were uveitis specialists, however,
and so these results undoubtedly reflected the biases and
practice patterns of the particular population surveyed.
In this issue of the Journal of Ophthalmic Inflammation
and Infection, Esterberg and Acharya provide additional
insights into the use of corticosteroid-sparing immunomod-
ulatory therapy for chronic noninfectious uveitis [12]. The
authors summarize responses from a group of 45 uveitis
specialists identifiedelectronicallyusing the AUS and Proctor
Foundation e-mail LISTSERVs. Sixty-eight percent of
respondents practiced in a university or academic setting and
73% had 6 or more years experience treating uveitis. One
might presume, therefore, that the vast majority of the partic-
ipants had both knowledge and experience regarding previ-
ously published uveitis treatment guidelines [11]. This viewis
supported by the fact that the median acceptable maintenance
dose of oral prednisone reported by the respondents was
7.5 mg/day and was in all instances at or less than the
10mg/dayrecommendedbythesesameguidelines.Anumber
of interesting observations were made by the authors. First,
antimetabolites, most notably methotrexate and mycopheno-
late mofetil, tended to be the most preferred and first used
immunosuppressive agents despite onlymodest effectiveness,
both perceived [12] and actual—at least as measured by
control of inflammation and corticosteroid-sparing success
rates [13–15]. This approach appears to have come from
complexconsiderationsregardingcost,easeofadministration,
and availability of long-term efficacy and tolerability data.
Conversely, the alkylating agent cyclophosphamide and the
TNF-α inhibitors were both less preferred and less frequently
used, despite higher perceived effectiveness. Concerns
seemed to center around safety/tolerability in the case of
cyclophosphamide, whereas cost, lack of long-term data,
and to a lesser extent ease of administration were the major
reasons for not prescribing TNF-α inhibitors. Respondents
were not queried regarding the use of chlorambucil [16–18],
etanercept [19–23] or the interferons [24, 25] despite reports
of therapeutic benefit with these agents in selected patients
with uveitis. Second, the most favored agent for the treatment
of intermediate and posterior/panuveitis was mycophenolate
mofetil, a preference supported at least in part by high success
rates with this agent in the Systemic Immunosuppressive
Therapy for Eye (SITE) Diseases Cohort Study [14, 15, 26].
Third, azathioprine was generally the least favored antimetab-
olite regardless of anatomical localization of the inflammation,
despite the fact that a number of randomized trials comparing
azathioprinetomethotrexateinvariousrheumatologicdiseases
andtopreventorganrejectionpost-transplantationhaveshown
similar efficacy and tolerability [12]. Andfourth,cyclosporine,
the only leukocyte signaling inhibitor queried, was rarely
preferredandinfrequentlyused,dueprimarilytoconcernsover
tolerability. Such perceptions appear to be supported, at least
partially, by the findings of the SITE Study group, which
reported relatively low corticosteroid sparing success with
cyclosporine [15, 27]. Moreover, adverse events tend to in-
crease with age in patients treated with cyclosporine and are
particularly common in the elderly [27].
Taken together, published practice surveys in uveitis
highlight several important points. First is the need for
improved education and wider dissemination of evidence-
based reviews regarding uveitis treatment—particularly to
non-specialists who care for a sizable proportion of patients
with uveitis [28]. Second is the importance of practical and
timely treatment guidelines promulgated by those most
knowledgeable in the field—either as expert panel recom-
mendations [11] or true consensus guidelines [29]. Perhaps
surprisingly, such treatment recommendations or guidelines
do not yet exist for ocular toxoplasmosis—the most com-
mon cause of infectious uveitis worldwide [30, 31], and
while guidelines do exist regarding the use of immunosup-
pressive drugs in patients with noninfectious uveitis, they
are largely unknown by all but those already quite experi-
enced in the use of such agents. Moreover, current treatment
guidelines for uveitis are more than 10 years old, provide
little information regarding treatment goals or endpoints
when using individual or combined therapies to treat spe-
cific conditions or complications of uveitis, and include
relatively little mention of the newer biologic agents. It is
perhaps time, therefore, to consider introducing evidence-
based treatment recommendations or guidelines for ocular
toxoplasmosis and updating existing guidelines on the use
of immunomodulatory agents to treat ocular inflammatory
disease, including recent data on the use of TNF-α inhibitors
and the interferons. And third is the importance of standard-
ized outcome metrics in uveitis treatment studies [15]. Per-
ceptions and preferences are noteworthy, but are by no means
substitutes for data obtained from well-designed studies, be
they retrospective and observational or, when feasible and
appropriate, prospective and randomized.
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